Mezzion Pharma Shares Promising Preclinical Data for Udenafil in Treating ADPKD

According to Mezzion Pharma and investigators at Mayo Clinic in Florida, a preclinical study of udenafil — a phosphodiesterase type 5 inhibitor — produced statistically significant reductions in kidney cyst burden and blood urea nitrogen in a model of autosomal dominant polycystic kidney disease (ADPKD), reinforcing the case for a planned Phase 2b trial in patients at risk of rapid progression.

The study, reported by the company on August 2, 2026, recorded statistically significant reductions in both cyst burden and BUN — a blood marker tied to kidney function — versus controls. The effect held across treatment groups. Researchers also observed activity on the cyclic guanosine monophosphate (cGMP) signaling pathway that udenafil is designed to engage, and a separate statistically significant drop in a preclinical measure of cardiac hypertrophy, a frequent complication of ADPKD. Fouad T. Chebib, M.D., served as principal investigator.

Building on earlier signals

This is the third preclinical dataset for udenafil in ADPKD. Two prior studies had already shown cyst-growth inhibition and reduced cyst burden. The convergence across models — same mechanism, same disease phenotype, three independent experiments — is what researchers typically flag as biologically meaningful rather than incidental.

"The consistency across multiple preclinical models is encouraging and supports evaluating udenafil in a well-designed Phase 2b study using established measures of ADPKD progression," said Ronald D. Perrone, M.D., of Tufts Medicine.

A different mechanism on the table

Current approved therapies for ADPKD include vasopressin V2 receptor antagonists. Udenafil operates through a separate axis — the nitric oxide-cGMP pathway — making it a mechanistically distinct candidate. Professor Yong Chul Kim of Seoul National University Hospital, who plans to participate in the upcoming trial, put the appeal plainly: "Unlike vasopressin V2 receptor antagonists, udenafil is being investigated through modulation of the nitric oxide-cGMP pathway, providing a mechanistically distinct therapeutic approach."

What to watch next

Mezzion says the U.S. Food and Drug Administration has indicated that the company's nonclinical data package, combined with roughly two decades of clinical and safety experience with udenafil in other programs, provides a reasonable foundation for clinical development. The concrete next milestones: protocol finalization for a Phase 2b study in adults at risk of rapidly progressing ADPKD, followed by regulatory and ethics approvals. The company is also running a separate Phase 3 trial called FUEL-2 in another rare-disease indication.

For the roughly 1 in 400 to 1,000 people worldwide living with ADPKD — and the clinicians managing progressive cyst growth, declining filtration, and the cardiac complications that travel with it — the practical question is whether the Phase 2b protocol moves to enrollment this year. Until then, the data is preclinical, and the only legitimate readout is statistical, not clinical.